Similar articles

• New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.

  Antoñanzas F, Gómez P. Antoñanzas F, et al. Pharmacoeconomics. 2010;28(11):977-80. doi: 10.2165/11535780-000000000-00000. Pharmacoeconomics. 2010. PMID: 20936881 No abstract available.
• Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.

  Sandmann FG, Franken MG, Steenhoek A, Koopmanschap MA. Sandmann FG, et al. Health Policy. 2013 Oct;112(3):285-96. doi: 10.1016/j.healthpol.2013.03.006. Epub 2013 Apr 28. Health Policy. 2013. PMID: 23628483
• Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.

  Murry L, Gerleman B, Urick B, Urmie J. Murry L, et al. J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4):421-425. doi: 10.1016/j.japh.2018.04.018. Epub 2018 May 31. J Am Pharm Assoc (2003). 2018. PMID: 29861152
• [Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement].

  Wilkowsky C, Lenain A, Benbekhaled K, Le Gall MJ, Vignot S. Wilkowsky C, et al. Bull Cancer. 2016 Apr;103(4):353-60. doi: 10.1016/j.bulcan.2016.02.010. Epub 2016 Mar 24. Bull Cancer. 2016. PMID: 27017057 Review. French.
• Comparison of prescription reimbursement methodologies in Japan and the United States.

  Akaho E, MacLaughlin EJ, Takeuchi Y. Akaho E, et al. J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):519-26. doi: 10.1331/154434503322226275. J Am Pharm Assoc (2003). 2003. PMID: 12952317 Review.